Compare WLDN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | VIR |
|---|---|---|
| Founded | 1964 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2006 | 2019 |
| Metric | WLDN | VIR |
|---|---|---|
| Price | $87.00 | $11.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $114.50 | $19.43 |
| AVG Volume (30 Days) | 201.9K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | 17.49 |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $273,352,000.00 | $68,556,000.00 |
| Revenue This Year | N/A | $270.22 |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | $40.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $64.67 | $4.75 |
| 52 Week High | $137.00 | $11.94 |
| Indicator | WLDN | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 61.65 |
| Support Level | $72.52 | $8.43 |
| Resistance Level | $88.72 | $11.66 |
| Average True Range (ATR) | 2.85 | 0.67 |
| MACD | -0.15 | 0.10 |
| Stochastic Oscillator | 74.81 | 73.41 |
Willdan Group Inc is a technical services company focused on energy and infrastructure solutions. The company's solutions include energy planning and analytics, consulting, software, public finance, engineering, and program implementation. It operates through two segments: i) Energy segment: It provides specialized, comprehensive energy solutions to businesses, utilities, state agencies, municipalities, and non-profit organizations. ii) Engineering & Consulting: It provides civil engineering and construction management, building and safety services, city engineering and planning support, civil design, geotechnical services, and material testing. The majority of revenue is derived from the Energy segment. Geographically, all of the company's revenue is generated from the United States.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.